Journal
HEPATOLOGY INTERNATIONAL
Volume -, Issue -, Pages -Publisher
SPRINGER
DOI: 10.1007/s12072-023-10594-x
Keywords
ctDNA; Liver cancer; Liver transplantation; MRD; Tumor recurrence
Categories
Ask authors/readers for more resources
This study reveals that ctDNA can effectively detect minimal residual disease (MRD) and predict tumor recurrence in liver cancer patients undergoing liver transplantation. The mutational profiles of ctDNA are highly concordant with those of tumor tissues. Positive ctDNA status is associated with higher recurrence rate and shorter recurrence-free survival. Serial monitoring of ctDNA can predict recurrence ahead of imaging evidence and serum tumor biomarkers.
Background Minimal residual disease (MRD) is proposed to be responsible for tumor recurrence. The role of circulating tumor DNA (ctDNA) to detect MRD, monitor recurrence, and predict prognosis in liver cancer patients undergoing liver transplantation (LT) remains unrevealed.Methods Serial blood samples were collected to profile ctDNA mutational changes. Baseline ctDNA mutational profiles were compared with those of matched tumor tissues. Correlations between ctDNA status and recurrence rate (RR) and recurrence-free survival (RFS) were analyzed, respectively. Dynamic change of ctDNA was monitored to predict tumor recurrence.Results Baseline mutational profiles of ctDNA were highly concordant with those of tumor tissues (median, 89.85%; range 46.2-100%) in the 74 patients. Before LT, positive ctDNA status was associated with higher RR (31.7% vs 11.5%; p = 0.001) and shorter RFS than negative ctDNA status (17.8 vs 19.4 months; p = 0.019). After LT, the percentage of ctDNA positivity decreased (17.6% vs 47.0%; p < 0.001) and patients with positive ctDNA status had higher RR (46.2% vs 21.3%; p < 0.001) and shorter RFS (17.2 vs 19.2 months; p = 0.010). Serial ctDNA profiling demonstrated patients with decreased or constant negative ctDNA status had lower RR (33.3% vs 50.0%; p = 0.015) and favorable RFS (18.2 vs 15.0 months, p = 0.003) than those with increased or constant positive ctDNA status. Serial ctDNA profiling predicted recurrence months ahead of imaging evidence and serum tumor biomarkers.Conclusions ctDNA could effectively detect MRD and predict tumor recurrence in liver cancer patients undergone LT.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available